Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia

Authors: Stilgenbauer, Stephan, Tausch, Eugen, Roberts, Andrew W., Davids, Matthew S., Eichhorst, Barbara, Hallek, Michael, Hillmen, Peter, Schneider, Christof, Schetelig, Johannes, Böttcher, Sebastian, Kater, Arnon P., Jiang, Yanwen, Boyer, Michelle, Popovic, Relja, Ghanim, Majd T., Moran, Michael, Sinai, Wendy J., Wang, Xifeng, Mukherjee, Nabanita, Chyla, Brenda, Wierda, William G., Seymour, John F.

Source: In Blood Advances 23 April 2024 8(8):1992-2004

Treatment Effectiveness with Venetoclax-Based Therapy after Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

Authors: Ghosh, Nilanjan, Lamanna, Nicole, Eyre, Toby A., Coombs, Catherine C, Manzoor, Beenish S, Brown, Jennifer R., Tuncer, Hande H., Ujjani, Chaitra S, Leslie, Lori A, Roeker, Lindsey E., Davids, Matthew S, Rhodes, Joanna M., Skarbnik, Alan, Emechebe, Nnadozie, Fleury, Isabelle, Hill, Brian T., Fox, Christopher P., Barr, Paul M., Jawaid, Dureshahwar, Sinai, Wendy J, Pearson, Laurie K, Lansigan, Frederick, Choi, Yun, Jensen, Christopher E., Schuster, Stephen J., Kennard, Kaitlin, Pivneva, Irina, Watson, Talissa, Guerin, Annie, Shadman, Mazyar

Source: In Blood 2 November 2023 142 Supplement 1:1908-1908